Aurobindo Pharma has reported results for first quarter ended June 30, 2014.
The company’s net profit after tax has jumped around three fold at Rs 393.40 crore as compared to Rs 143.63 crore for the quarter ended June 30, 2013. Its total income has increased by 21.19% to Rs 1956.69 crore for the quarter under review from Rs 1614.61 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported over 22 fold jump in its net profit after taxes and minority interest at Rs 415.43 crore for the quarter as compared to Rs 18.60 crore for the same quarter in the previous year. Its total income has increased by 69.93% at Rs 2921.88 crore for quarter under review as compared to Rs 1719.48 crore for the quarter ended June 30, 2013.
During the quarter Agile Pharma B.V-Netherlands, a step down subsidiary of the company has acquired select Western European business of Actavis. The above consolidated results for the current quarter ended June 30, 2014 includes the results of the operation of the above business of Actavis from April 01, 2014. The corresponding figures for the previous periods are not comparable.
